imatinib mesylate has been researched along with Margins of Excision in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Berman, RS; Lee, AY; Vitiello, GA | 1 |
| Ahn, JB; Cheong, C; Kang, J; Kim, NK; Lee, KY; Min, BS | 1 |
| Buljan, M; Crnarić, I; Delaš Aždajić, M; Šitum, M; Vučić, M | 1 |
| Ahn, C; Allen, A; Sangüeza, OP | 1 |
| Brosens, LAA; Gertsen, EC; Ruurda, JP; van Boxel, GI; van Hillegersberg, R | 1 |
| Baia, M; Bastiaannet, E; Desar, IME; Farag, S; Gelderblom, H; Gronchi, A; Hohenberger, P; IJzerman, NS; Jones, RL; Martin-Broto, J; Mohammadi, M; Oosten, AW; Reyners, AKL; Rutkowski, P; Schöffski, P; Schrage, Y; Steeghs, N; van Sandick, JW; Vassos, N | 1 |
| Bjerkehagen, B; Boye, K; Hompland, I; Hølmebakk, T; Stoldt, S | 1 |
2 review(s) available for imatinib mesylate and Margins of Excision
| Article | Year |
|---|---|
Dermatofibrosarcoma Protuberans: What Is This?
Topics: Dermatofibrosarcoma; Humans; Imatinib Mesylate; Margins of Excision; Skin Neoplasms | 2022 |
Dermatofibrosarcoma Protuberans.
Topics: Antineoplastic Agents; Dermatofibrosarcoma; Dermatologic Surgical Procedures; Humans; Imatinib Mesylate; Margins of Excision; Mohs Surgery; Oncogene Proteins, Fusion; Skin Neoplasms; Translocation, Genetic | 2019 |
5 other study(ies) available for imatinib mesylate and Margins of Excision
| Article | Year |
|---|---|
Impact of neoadjuvant treatment on rectal gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Margins of Excision; Neoadjuvant Therapy; Rectal Neoplasms; Retrospective Studies | 2022 |
From Morphea to Dermatofibrosarcoma Protuberans.
Topics: Adult; Cicatrix; Dermatofibrosarcoma; Disease Progression; Female; Follow-Up Studies; Histiocytoma, Benign Fibrous; Humans; Imatinib Mesylate; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Scleroderma, Localized; Skin Neoplasms; Young Adult | 2022 |
Minimally Invasive Resection of Large Gastric Gastrointestinal Stromal Tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Conversion to Open Surgery; Disease-Free Survival; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intraoperative Complications; Laparoscopy; Length of Stay; Male; Margins of Excision; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Postoperative Complications; Retrospective Studies; Stomach Neoplasms; Tumor Burden | 2020 |
Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study.
Topics: Aged; Anastomotic Leak; Antineoplastic Agents; Biopsy, Fine-Needle; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Esophagoscopy; Europe; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Margins of Excision; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Neoplasm Metastasis; Plastic Surgery Procedures; Postoperative Complications; Progression-Free Survival; Retrospective Studies; Treatment Outcome; Tumor Burden | 2021 |
Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour.
Topics: Adult; Aged; Databases, Factual; Digestive System Surgical Procedures; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hospitals, University; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Norway; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Rupture; Survival Analysis; Treatment Outcome | 2019 |